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Probiotics are nonpathogenic bacteria exert a constructive influence on health or 
physiology of the host. Effect of probiotics in the intestinal defense against variety 
of diseases is well known. The probiotics are involved in the mechanism of 
intestinal defense, support as antagonist against pathogens, improve intestinal 
epithelial layer and boost the innate as well as adaptive immunity. However these 
responses are also exerted by intestinal components. The intestinal components as 
well as probiotics play a reciprocal role to enhance the immune response of the 
individual. The possibilities of mechanism of action include the stimulation of 
epithelial cells, activation of dendritic cells via toll-like receptors (TLRs), 
conversely produce cytokines. These observations reviewed together advocate that 
specific immunomodulatory properties of probiotic bacteria should be focusing on 
mechanism of action via antigen presenting cells (APC). 
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INTRODUCTION 
 
Probiotics are live microbial feed/or food 
supplements or components of bacteria which have 
beneficial effects on animal and human health. The 
healthy animal and/or human consist of about 100 trillion 
cells, carries about ten times as many microorganisms in 
the intestines including both groups’ useful and 
potentially harmful microorganisms (Guarner and 
Malagelada, 2003). The most frequent passage for the 
entry of bacteria is digestive tract, and natural security of 
the digestive tract is controlled by useful bacteria called 
‘friendly’ bacteria. When these friendly bacteria are not 
capable to defend the host against pathogens, the harmful 
bacteria invade the tissues and produce hazardous toxins 
and their metabolites (Brock and Madigan, 1991) 
conversely; the host can fight against pathogens through 
their defense mechanisms. But, in the war of survival, 
occasionally pathogen succeeds, and need a 
complementary preventive and control measures (Oyetayo 
and Osho, 2004). Chemotherapeutic drugs have been 
applied to control the pathogenic microorganisms, but 
with the passage of time these drugs developed resistance 
in the animals as well as in population of the bacteria, 
herewith, liberate toxic effects in the host. The live 
biotherapeutic alternative such as probiotics (Gillingham 
and  David, 2009)  has  been  regarded  as   alternative   of 
antibiotics. Probiotics have supportive effect on the health 
of host by producing an affirmative balance of digestive 
microflora, increase in antioxidant functioning  and 
restraining the damage caused by pathogenic 
microorganisms (Shen et al., 2011), improving epithelial 
cell integrity and increasing immune response (Vanbella 
et al., 1990; Jin et al., 2000; Wenk, 2000; Panda et al., 
2001; Linge, 2005). Preventive application of probiotics 
achieves better utilization of nutrients and has a positive 
effect on environment of gastrointestinal tract (Capcarova 
et al., 2009). Useful probiotic strains include the members 
of genera Enterococcus, Bifidobacteriaum,  Latobacillus, 
Bacillus, Lactococcus, Propionibacterium, Saccharomyces, 
Streptococcus,  and their probio-active (cellular) 
substances that have awesome influence on the intestinal 
and non intestinal physiology of host. Many species of 
probiotics are used in prevention of intestinal affliction, 
such as constipation, diarrhea, reverse peristaltic movement 
and accumulation of gases etc (Miles et al., 2006; Huang 
et al., 2012). The current review presents an overview on 
beneficial effects of probiotics mainly focusing on 
maintaining healthy intestine, their mechanism of action 
and enhancing the cytokine response by antigen 
presenting cells (APC) via TLR signaling, that is one of 
the strong tools of multicellular organisms against 
pathogens by supporting signaling response.  
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Beneficial Effects of Probiotics to Intestinal Afflictions 
Lactose Intolerance:  The lactose intolerance is an 
inability of gastro intestinal tract (GIT) to absorb lactose 
(predominant sugar of milk), resulting in an increased 
osmotic pressure in the small intestine with fluent 
secretion of fluids (Launiala, 1968; Lasser et al., 1975). 
Fermented milk products have been observed to be 
tolerated well by lactose maldigesters as compared to 
milk, these properties might be valuable for lactose 
intolerant individuals (Vesa et al., 2000).  Somewhat 
probiotics species producing lactase, such as Lactoba- 
cillus, contain (beta) galactosidase or intracellular lactose; 
have a role in getting relief from lactose intolerance 
symptoms (Sanders, 2000). However, the mechanism of 
action of probiotics against lactose intolerance requires 
resolving mounting issue. 
 
Diarrhea:  Diarrhea  is an increase in the frequency of 
defecation, bowel evacuation and water content of the 
stool. Now-a-days, various mechanisms have been 
described to avert the diarrhea. The first mechanism was 
active blockage of receptor sites (Bernet, 1994) and this 
theory might be logical if there is an evidence for 
competition of specific receptors (Lundgren and 
Svensson, 2001). Somehow lactobacilli response to 
compete with the peptides released from villous endocrine 
cells or toxin, and the force that leads to diarrhea could be 
prevented (Reid et al., 2002). The other mechanism is 
supported by the local immunoglobolin A (IgA) antibody 
effective against the rotavirus (Kaila et al., 1992). Animal 
studies indicate that secretory IgA can be triggered by 
lactobacillus ingestion, but the negative aspect of this 
theory is that high concentration of causative agents may 
drop the effect of secretory IgA (Reid et al., 2002). 
However, the third mechanism involves the signals from 
probiotics (Lactobacilli) to the host that regulate the 
intestinal defense to eliminate perceived noxious 
secretions (Yolken, 1994). Mucins (Glycosylated in 
nature) secreted by intestine play an active role to inhibit 
rotaviruses. It has been confirmed that MUC2 and MUC3 
mRNA expression increase in response to lactobacillus 
signaling, protect cells against harmful bacterial adhesion 
(Mack  et al., 1999). The last theory involves that 
probiotics could produce substances that inactivate the 
active particles (Cadieux et al., 2002). The probable effect 
may be due to acid, but more specific antiviral properties 
have not been ruled out yet (Reid et al., 2002). The 
mechanism of probiotic may be different depending on 
the cause of diarrhea. The cell receptors have a vital role 
in signaling to initiate and control the cellular response to 
develop the immunity.  
 
Constipation:  Constipation is one of the major GIT 
problems in animals as well as human beings, and 
provides an opportunity for pathogens to invade intestinal 
mucosa. Peristaltic movement of the intestine is 
responsible for defecation, and helps in excretion of the 
harmful agents from the body. Constipation may be due to 
insufficient liquid intake, low-fiber diets, physical 
inactivity and some drugs etc. A modified faecal 
microflora with reduced levels of bifidobacteria, 
Bacteroides and particularly reduced levels of clostridia 
were reported while investigations were made on affected 
individuals (Shimoyma et al., 1984; Arthur, 2002). 
Probiotics have proved to be effective to get relief from 
constipation (Goldin, 1998), hence a comprehensive study 
on the mechanism of action of probiotics in constipation is 
the prime need of time. 
 
Colon Cancer: Procarcinogens convert into carcinogens 
in intestinal tract and become the cause of colon cancer, 
while specific strains “probiotic” (L. acidophilus) 
neutralize the procarcinogens. A number of super strains 
are capable to metabolize procarcinogens that could revert 
them into noncarcinogenic material. Such step may be 
preceded by an activation of metabolites a precursor of 
carcinogen production (Walker,  20008). Certain active 
enzymes (such as nitro-reductase and beta-glucuronidase) 
that convert procarcinogen substances into carcinogenic 
material are tainted by helpful microbes by removing their 
damaging properties (Wen et al., 2009). Literature 
manifest that some species of probiotics might be applied 
for the treatment of cancer. However reliable findings are 
not accessible in citations.  
 
Inflammatory Bowel Disease:  Inflammatory bowel 
disease (IBD) is characterized clinically by two 
overlapping phenotypes, ulcerative colitis (UC) and 
Crohn’s disease (CD), both chiefly affect the colon (UC 
and CD) and/or the distal small intestine (CD). The 
etiology of disease is not absolutely understood, but a 
genetic tendency and the friendly intestinal microflora are 
thought to perform an imperative role (Mattila- Sandholm 
et al., 1999). Modification in the composition and general 
activity of the useful microflora may give good results 
against the disease. Some selected probiotics have been 
investigated to condense the number of relapses and 
extend the period of remission (Hamilton-Miller, 2001). 
Interestingly, not only L. salivarius UCC118, and L. 
rhamnosus GG, but also S. cerevisiae (boulardii) and a 
strain of E. coli (Nissle) have been beneficiated in 
alleviating the symptoms of IBD (Gupta et al., 2000; 
Guslandi et al., 2000). But, additional investigations on 
the mechanism of action in detail are obligatory to 
elucidate the mitigation of IBD, symptoms by probiotics.  
 
Necrotizing Enterocolitis:  Necrotizing enterocolitis 
(NEC) is one of the challenging diseases in infants. NEC 
pathophysiology has been observed multifactorial and 
only been elucidated to some extent (Vander et al., 2005; 
Lin and Stoll, 2006). Theoretically, association of targets 
is a positive adaptation in the intestinal flora which could 
consist of an efficient process of preventing the 
commencement of NEC (Deshpande et al., 2007). 
Contemporary data have shown that a lower incidence of 
NEC in the group supplemented with Lactobacillus GG 
than in the placebo-supplemented control group (1.4 vs 
2.7%) (Dani, et al., 2002), B. breve administration can 
promote colonization by Bifidobacterium, and may also 
stimulate mucosal immunity and immunological 
development of VLBW infants (Li et al., 2004). 
Bifidobacterium infantis supplementation extensively 
reduces the incidence of NEC (Caplan et al., 1999). It is 
confirmed that probiotics have their own functioning 
mechanism and capacity to reduce the possibility of NEC.   Pak Vet J, 2012, 32(3): 303-308.  305
 
 
 
Fig. 1: A systemic presentation of intestinal cells and possible mechanism of action of probiotic and   response of intestinal cells (Riina, 2008). 1) 
Modulation of commensal bacteria; 2) Competition with pathogen (receptor and nutrients); 3) Inhibition of pathogen attachment with intestinal wall; 
4) Production of antimicrobial agents against pathogen; 5) Strengthening of the mucosal barrier; 6) Inducing mucin production. 
 
 
 
Fig. 2: The diagram shows systemic defense of intestinal lining, cytokine 
production in response of invading pathogen and beneficial probiotics, 
while key cells interacting with systemic response between pathogen 
and probiotics. 1) Invading bacteria adhering on epithelia cells wall; 2) 
Attachment of probiotic without invading epithelial cells; 3) Commensal 
bacteria incorporation with probiotics; 4) Dendritic cells (APC) 
presenting antigen of probiotics to immunomodulation; 5) Phagocytosis 
in inflammation region; 6) Blood vessel containing cellular production, in 
response of pathogen; 7) Cytotoxic T cell to Phagocytosis activity in 
inflammation part. Tr1 production to maintain the balance of Th1 and 
Th2; 8) Response of Th1 and synthesis of INF￿, IL-2 and IL-12; 9) 
Production of IL-4, IL-5 and IL-13; 10) Th3 active to produce TGF. 
 
Beneficial effects for Homeostasis: In the contemporary 
emergent globe, use of the probiotics in healthy subjects 
has become the part usual diets. However, information 
about probiotics is complex, although it plays a significant 
role since probiotics have mainly been marketed for the 
betterment of healthy subjects and widely used in food, 
medicine, and husbandry industries (Qin et al., 2007). The 
effects of probiotics on healthy subjects are anticipated to 
be limited to hazard risk reduction (Tuomola et al., 2000; 
Ouwehand  et al., 2001). Generally probiotics are often 
available in markets having adhering antagonizing, 
defensive and epithelial supporting characteristics. The 
enduring evidence suggests that, long term use of 
probiotics may decrease the risks for infections, absence 
of illness in early age (Hatakka et al., 2001). The 
conclusion of this investigation showed that probiotics can 
also be utilized by healthy animal as well as human 
beings, by keeping in view their beneficial effects.  
 
Mechanism of Probiotics in the Intestinal Defense: The 
defense system of intestine can be enhanced by the 
application of probiotics as they produce their beneficial 
effects by diverse mechanisms such as antagonist against 
pathogen, improves intestinal epithelial layer and boost 
the innate immunity as well as support in adaptive 
immunity.  
 
Antagonistic effects against pathogens: Probiotics act as 
an antagonist against pathogens by producing antibacterial 
and antimicrobial compounds such as cytokines and 
butyric acid (Kailasapathy and Chin, 2000), also reduce 
gut pH by stimulating lactic acid producing microflora 
and favorably adjust the intestinal microflora balance 
(Langhendries  et al., 1995). They have the capacity to 
change the metabolism and composition of commensal 
microbiota to enhance the defense against pathogens 
(Siigur et al., 1996; Kuisma et al., 2003) and also inhibit 
lethal organisms adhesion by competing exclusion, in 
vitro  models, as has been reported in  Latobacillus, 
Propionibacterium and Bifidobacterium  strains (Collado 
et al., 2006; Collado et al., 2007). Probiotics compete for 
binding on receptor sites that can be occupied by 
pathogens (Fujiwara, 1997; Kailasapathy and Chin, 2000); 
also boost immune system and stimulate immunomodula- 
tory cells (Isolauri et al., 1995). Furthermore, compete 
with pathogens for accessible nutrition and other growth 
factors (Rolfe, 2000). These all findings confirm that 
probiotics are strong tool as antagonist and further detail 
investigations are need of time. Pak Vet J, 2012, 32(3): 303-308.  306
Improving Epithelial Structure: The intestinal epithelium 
is rapidly and constantly transformed by epithelial stem 
cells inhabitants. The stem cell population varies into 
numerous intestinal epithelial cell types, specific in their 
functions such as Goblet cells, Entero endocrine cells, 
Enterocytes, Paneth cells and M cells. These epithelial 
cells serve as a physical barrier between the luminal 
contents (commensal microbiota, food antigens and also 
probiotics) and the complex mucosal immune system 
(McCracken and Lorenz, 2001). The secretions of 
probiotics improve the continuous interaction of healthy 
intestinal linings with interacting pathogens. With this, 
also play a critical role to initiate the innate as well as 
adaptive immunity in the host. 
 
Boost Intestinal Immunity: Immunological reactions are 
divided into two parts by their specificity and speed of the 
reaction; in response to innate and adaptive immunity 
(Parkin and Cohen, 2001). Furthermore, the probiotics 
application  in vivo illustrated that; modern approaches 
could activate innate and adaptive immunity (Li et al., 
2011). The innate immunity provides instant but, non-
specific immunity to host defense, and includes physical, 
chemical, and microbiological barriers as well as support 
in several fundamentals of the immune system, such as 
neutrophils, monocytes, macrophages, complement, 
cytokines, and proteins active responses (acute-phase). 
However, their activation is most imperative which is 
initiated by intestinal epithelial cells, the most important 
APC and macrophages respectively. The adaptive 
immunity comprises antigen-specific reactions through T 
and B lymphocytes, take several days to develop, that 
works against specific invading pathogens. However, the 
cells are most reliable source for initiation of innate and 
adaptive immunity via their receptor signaling and 
transduction activity. Furthermore, several aspects of 
further studies related to mechanism of action of 
probiotics still requires focal point for researchers to 
hypothesize the mode of action, and response of dendritic 
cell (TLRs).  
 
Importance of Intestinal Cells Receptor Signaling: 
Activation of the host defense mechanisms is based on 
hasty detection of specific structural components of 
microorganisms also known as pathogen-associated 
molecular patterns (PAMPs), it includes peptidoglycan, 
lipopolysaccharide (LPS), lipoprotein, , lipoteichoic acid, 
flagelline and CpG-containing (unmethylated) DNA 
(Sansonetti, 2004; Alexopoulou and Kontoyiannis, 2005; 
Winkler et al., 2007). These components are identified by 
pattern-recognition receptors, and the best known are 
Toll-like receptors (TLRs) (Underhill, 2007). TLR family 
includes at least 13 proteins that recognize microbe 
derived ligands. For example, TLR1 and TLR2 recognize 
lipoproteins and lipid-modified sugars TLR4 recognizes 
LPS, TLR5 is activated by flagelline whereas TLR9 
recognizes CpG motifs in bacterial DNA (Underhill, 
2007). In general, the stimulation of TLRs by PAMPs 
consequences to the activation of adaptor proteins and this 
initiates a signaling cascade involving several kinases. 
However, some of Gram positive probiotics (highly 
flagelline in there structure), their membrane secrets 
lipoproteins and lipid-modified sugars, and activates 
TLR1-2 and TLR5 initiated to transcription of gene 
leading to the synthesis of immunomodulatory molecules. 
But, estimation of TLR1-2 and TLR5 and the mechanism 
of action are ambiguous.  
 
Cytokine Production in Response of TLR Signaling: 
Cytokines are known as diminutive proteins secreted by 
immune and many other types of cells (Sarah et al., 2010). 
Each cytokine may have multiple activities in unusual 
circumstances and cell types. Their action depends on 
binding with specific receptors present on the surface of 
cell and by stir up changes in the development, growth, 
and/ or activity of the target cells (Kidd, 2003). Different 
production patterns of cytokine are applied to segregate T 
helper cell (Th) responses to dissimilar classes. Th1-type 
cells generate IFN-γ, IFN-α, IL-2, IL-12 and also endorse 
cell-mediated immunity (Kidd, 2003). The second type of 
T-Helper cells (Th2-type) produce different interleukins 
mainly including IL-4, IL-5, IL-6, and IL-13 and trigger 
antibody-mediated immune response as well as mast and 
eosinophils cells (Wu et al., 2007). Th3-type cells 
function against Th1 and Th2, and they down regulate the 
inflammatory retort through TGF-β production and Tr1 
cells are responsible to maintain the balance in between 
immunity through IL-10 production (Izcue and Powrie, 
2008; Taylor et al., 2006). Cytokines can be categorized 
according to their production, including pro inflammatory, 
inflammatory and anti-inflammatory interleukins. Pro 
inflammatory cytokine, TNF-α is responsible to activate 
local inflammation concerned with immune system 
(Bertazza and Mocellin, 2008). TNF-α is production of 
professional immune cells like NK cells, T cells and 
macrophages, but non-immune cells also take part to 
produce like epithelial cells. These cells are capable to 
induce TNF-α, IL-1β, but mainly produced by 
macrophages and epithelial cells and further participate in 
macrophage and T cell activation (Barksby et al., 2007).  
The second one is inflammatory cytokines that 
include IL-1α/β (Barksby et al., 2007), TNF-α (Bertazza 
and Mocellin, 2008), IFN-γ (Schoenborn and Wilson, 
2007) and IL-6 (Gabay, 2006). Whereas IFN-γ, produced 
by T cells and NK cells, also possess antiviral activity and 
activates macrophages and suppresses Th2 responses 
(Schoenborn and Wilson, 2007). And involve in systemic 
effects of inflammation, such as weight loss, fever and 
hepatic protein synthesis (acute-phase). IL-1 and IL-6 also 
mediate the same response in systematic inflammation. 
IL-2, produced by T cells and its proliferation is 
promoted, but concentration may fluctuate in different 
immune supporting organs (Yu et al., 2010). IL-4 and IL-
5 are produced by mast and T cells respectively. IL-4 
activates B cells, and is involved in the control of IgE and 
suppression of Th1 cells, while IL-5 induces growth and 
differentiation of eosinophils. IL-6 is produced by 
endothelial cells, macrophages, T cells and  is concerned 
with T- and B-cell growth and differentiation, acute phase 
response (Gabay, 2006). IL-12 induces the production of 
IFN-γ and differentiates Th2 cells to Th1-type cells and 
plays a key role to form a link between innate and 
adaptive immunity (Trinchieri, 2003). Dendritic cells and 
phagocytes produce IL-12 during infection in response to 
pathogens and also activate NK cells (Trinchieri, 2003). 
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regulatory cytokine and it can be produced by many types 
of cells (Couper et al., 2008). All through the infection, it 
inhibits the activity of Th1 cells, NK cells, & macro- 
phages, required for optimal pathogen clearance, but in 
addition contributes in tissue damage (Couper et al., 
2008). Further study is mandatory for documentation of 
APC cells receptor signaling and in response, production 
of cytokine in favor of host innate as well as adaptive 
immunity. 
 
Conclusions:  Immunomodulatory functions of bacteria 
from the resident intestinal microflora, and the mechanism 
involved in the TLR signaling are essential for the better 
understanding of immunomodulatory effects. The 
differences in genus, species or strain of probiotic 
organisms are reflected in their virtual immunomodu-
latory efficiency and signaling mechanism. However, 
production of antibacterial substances is also decisive 
incident in the generation of a successful probiotic effects 
in the development of innate and adaptive immunity. 
Although the mechanisms whereby probiotic components 
enhance the immune response have not been resolved, 
however, possibilities include activation of toll-like 
receptors, of dendritic cells or stimulation of intestinal 
epithelial cells and release of cytokines and chemokines. 
Although, the documentation pertaining to the TLR 
signaling mechanisms is lacking, whereby, probiotics 
elicit beneficial effects to facilitate animal as well as 
human beings. It is prime requisite to be acquainted with 
the mechanism that enhances the functioning prospects of 
probiotics.  
 
Future Prospects: It has been revealed from the literature 
that, studies concerning to antigen presenting cells (APC) 
receptors, (TLRs), signaling and transduction allied to the 
effects of probiotics is inadequate, whereby the effective 
understanding of signaling and transduction mechanism 
will be a milestone for prospect studies, and better 
indulgent of mechanism will support to acquire more 
imminent effects of probiotics, that may depend upon the 
physiological condition of the subject, consequently, the 
variation in same genus and species may be possible. 
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